Jeffrey Guss

Jeffrey Guss, a Manhattan psychiatrist and co-investigator in the NYU psilocybin trial, helps define the therapeutic promise of psychedelic treatment as more than a drug acting on the brain. He presents it as a meeting of biological and psychodynamic approaches, in which the experience itself—and the meanings patients make through it—can become part of treatment. His account links psychoanalytic ideas about the ego to the loosening of rigid patterns of thought, while his work preparing volunteers shows how a therapist’s words help shape the encounter without dictating its final interpretation.

Clinical Role and Therapeutic Framework

Guss entered the book’s account as a clinician involved in the NYU cancer study and as a co-investigator in research exploring psilocybin-assisted psychotherapy. He described psychiatry as divided between biologically based treatments and psychodynamic treatments, each struggling for legitimacy and resources. Psychedelic therapy, in his view, could bring those approaches together: it takes a drug’s biological action seriously, but also addresses mental illness as a disruption of meaning in a person’s life. The treatment is therefore neither simply pharmacological nor simply interpretive; its promise lies in joining the two.

That synthesis matters in a field where researchers cannot easily separate a psychedelic’s chemical action from the circumstances of its use. Participants and guides may recognize whether a person has received psilocybin or a placebo, and the volunteer’s expectations, the therapist’s presence, and the treatment environment may all influence the outcome. These are challenges for psychedelic research broadly, rather than claims unique to Guss. His therapeutic model nonetheless makes clear why those contextual factors are not incidental: the patient’s experience and the work of psychotherapy are part of what the treatment is meant to engage.

The Ego, Boundaries, and New Meaning

Guss interprets the session through the drug’s “egolytic” effects: its capacity to quiet, or at least muffle, the ego’s voice. In his psychoanalytic account, the ego is a mental construct that serves the self, maintaining boundaries between conscious and unconscious experience and between self and other. Under psychedelics, those boundaries may fade. Guss argues that this loosening can allow people to release rigid patterns of thought and perceive new meanings with less fear.

This framework offers a way to understand why the NYU team’s follow-up work examined patients’ own accounts of change, rather than treating the drug’s effects as a matter of symptoms alone. In the 2017 study “Patient Experiences of Psilocybin-Assisted Psychotherapy,” Guss was a coauthor. Interviewed volunteers described stronger feelings of connection to loved ones and a movement from separateness toward interconnectedness, often accompanied by joy, bliss, and love. Difficult passages in the sessions could give way to surrender and acceptance, including acceptance of their cancers. These findings belong to the patients’ reports and the study as a whole; Guss’s distinct contribution is the psychoanalytic interpretation of how a temporary weakening of the ego’s boundaries might make such shifts possible.

The distinction is important. Guss does not reduce the patients’ experiences to a single spiritual explanation, nor does his account dismiss their emotional significance. Instead, it offers a psychological mechanism through which altered boundaries may make fresh perspectives available. In a population confronting serious illness, the possibility of seeing oneself, other people, or one’s circumstances differently gives the therapeutic experience a significance that cannot be conveyed by describing the drug alone.

Preparation and the Therapist’s Influence

Guss’s role begins before the session. In preparing volunteers, he speaks directly about the possibility of acquiring meaning: he tells patients that the medicine may reveal hidden or unfamiliar parts of themselves, offer insight, and deepen their understanding of life and existence. He also allows for the possibility of a mystical or transcendent experience, but takes care not to define in advance what that experience must mean. The preparation thus sets an interpretive horizon while leaving the patient’s particular encounter open.

That balance reflects a central tension in psychedelic therapy. Guss’s own account recognizes that a person’s expectations and the guide’s presence can influence how an experience is understood. The therapist is not outside the process, neutrally observing a drug effect; preparation can help shape what patients notice and how they interpret it. Yet Guss’s restraint about naming or prescribing a mystical experience marks a limit on that influence. His approach makes room for meaning without fixing its content beforehand.

The practice also recalls, without making Guss a shaman or placing him in underground work, the wider tradition of guiding altered states through attention to context and expectation. The book describes psychedelic treatment as operating at an unsettled border between clinical science and spiritual language. Guss’s work makes that border concrete: a psychiatrist can discuss self-knowledge, life’s meaning, and transcendence while remaining part of a modern clinical study. His method depends on treating these matters as relevant to therapy, not as distractions from it.

Research Beyond Cancer Treatment

Guss’s work extended beyond the NYU cancer study. He collaborated with Stephen Ross and Michael Bogenschutz on a larger NYU phase 2 trial of psilocybin for alcohol dependence. The study followed an encouraging pilot at the University of New Mexico, where ten participants received psilocybin alongside motivational enhancement therapy. Drinking declined after the psilocybin session, and the reduction persisted through thirty-six weeks of follow-up; the reported strength of the psychedelic experience also correlated with its effect on drinking behavior. Bogenschutz was conducting the larger trial in collaboration with Ross and Guss.

The collaboration places Guss within a renewed investigation of addiction as a condition that may involve more than chemical dependence. In the book’s account, Ross describes alcoholism as a loss of connection in which life’s meaning narrows around alcohol. That formulation resonates with Guss’s emphasis on psychotherapy and meaning, though the evidence does not assign Ross’s specific explanation to Guss. Across the cancer and addiction studies, Guss’s documented role is to help develop a therapeutic model in which a guided psychedelic experience may be clinically consequential because of how it affects both mental processes and a person’s understanding of life.

Narrative Significance

Guss represents a contemporary effort to make room within psychiatry for forms of change that do not fit neatly into a division between brain chemistry and psychological meaning. His clinical position, psychoanalytic interpretation, and attention to preparation connect three levels of the treatment: the drug’s action, the patient’s experience, and the therapist’s part in creating conditions for that experience. The book does not present his account as a final explanation of psychedelic effects. Rather, it shows how his work gives researchers a language for discussing the therapeutic role of loosened mental boundaries while retaining the unresolved questions of expectation, context, and spiritual interpretation.

That unresolved quality is central to Guss’s significance. He is neither presented as an advocate of unqualified mysticism nor as a clinician who can explain the treatment through pharmacology alone. His approach asks modern psychotherapy to take the patient’s search for meaning seriously, while acknowledging that the experience is guided and interpreted within a therapeutic relationship. In this account, the therapist’s task is not to supply a complete meaning for the patient, but to help make a different kind of meaning possible.